Access the full text.
Sign up today, get DeepDyve free for 14 days.
C Male (2020)
e18Lancet Haematol, 7
MR Patel, KW Mahaffey, J Garg (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med, 365
P. Monagle, Anthony Chan, N. Goldenberg, R. Ichord, J. Journeycake, U. Nowak-Göttl, S. Vesely (2012)
Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest, 141 2 Suppl
BW McCrindle (2014)
1192Circulation, 130
BW McCrindle (2021)
e021765J Am Heart Assoc, 10
P. Monagle, A. Cochrane, B. McCrindle, L. Benson, W. Williams, M. Andrew (1998)
Thromboembolic complications after fontan procedures--the role of prophylactic anticoagulation.The Journal of thoracic and cardiovascular surgery, 115 3
L. Raffini, Yuan-Shung Huang, C. Witmer, C. Feudtner (2009)
Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007Pediatrics, 124
E Investigators, R Bauersachs, SD Berkowitz (2010)
Oral rivaroxaban for symptomatic venous thromboembolismN Engl J Med, 363
M. Prins, A. Lensing, R. Bauersachs, B. Bellen, H. Bounameaux, T. Brighton, A. Cohen, B. Davidson, H. Décousus, G. Raskob, Scott Berkowitz, P. Wells (2013)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 11
H. Yang, B. Bouma, K. Dimopoulos, P. Khairy, M. Ladouceur, K. Niwa, M. Greutmann, M. Schwerzmann, A. Egbe, G. Scognamiglio, W. Budts, G. Veldtman, A. Opotowsky, C. Broberg, L. Gumbiene, F. Meijboom, T. Rutz, M. Post, Tabitha Moe, M. Lipczyńska, S. Tsai, S. Chakrabarti, D. Tobler, W. Davidson, M. Morissens, A. Dijk, J. Buber, J. Bouchardy, K. Skoglund, C. Christersson, T. Kronvall, T. Konings, R. Alonso-Gonzalez, A. Mizuno, G. Webb, M. Laukyte, G. Sieswerda, K. Shafer, J. Aboulhosn, B. Mulder (2020)
Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study.International journal of cardiology
G Balling (2000)
745J Thorac Cardiovasc Surg, 119
T. Giglia, M. Massicotte, J. Tweddell, R. Barst, M. Bauman, C. Erickson, T. Feltes, E. Foster, K. Hinoki, R. Ichord, J. Kreutzer, B. McCrindle, J. Newburger, S. Tabbutt, J. Todd, C. Webb (2013)
Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association.Circulation, 128 24
Rivaroxaban is a direct oral anticoagulant approved for therapeutic and prophylactic anticoagulation in both adults and children. Studies on rivaroxaban use in pediatric patients with congenital heart disease (CHD) are limited. Currently, warfarin (oral) and enoxaparin (injection) are the primary options for pediatric outpatient anticoagulation. Rivaroxaban may be a less burdensome alternative, but its use has not been well described in the pediatric CHD population. We describe our single-center experience. From May 2020–July 2022, we identified all pediatric CHD patients started on rivaroxaban. Dosing was based on recommendations reported in the EINSTEIN-Jr (Male et al. in Lancet Haematol 7:e18–e27, 2020) and UNIVERSE study (McCrindle et al. in J Am Heart Assoc 10:e021765, 2021) protocols. Qualitative outcomes on safety and efficacy are reported. There were 27 patients studied with an age range of 4 months–15 years at time of medication initiation. Single ventricle heart disease was present in 70% (19/27) of patients. Of the 27 patients initiated on rivaroxaban, 15 (56%) were started for VTE prophylaxis and 12 (44%) were started for VTE treatment. No patients started on rivaroxaban for prophylaxis developed a VTE. There was resolution or lack of propagation in 10 of the 12 patients started for treatment. There were two clinically relevant bleeding episodes. Our single-center case series describes the experience with rivaroxaban for VTE prophylaxis and treatment in pediatric congenital heart disease. Larger studies are required to further investigate safety, efficacy, and use indications.
Pediatric Cardiology – Springer Journals
Published: Jan 21, 2023
Keywords: Rivaroxaban; Congenital heart disease; Venous thromboembolism; Fontan
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.